Portal de Periódicos da CAPES

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse

2005; Elsevier BV; Volume: 16; Issue: 4 Linguagem: Inglês

10.1093/annonc/mdi119

1569-8041

Anna Sureda, M. Constans, A Iriondo, R. Arranz, Marı́a Dolores Caballero, María‐Jesús Vidal, J Petit, Álvaro Marchán-López, Juan José Lahuerta, Enric Carreras, J Garcı́a-Conde, José García‐Laraña, R Cabrera, Isidro Jarque, D. Carrera, Juan Carlos García‐Ruiz, M. Pascual, J. Rifón, José M. Moraleda, Katy Perez‐Equiza, Carmen Albó, J Díaz-Mediavilla, A. Torres, Pilar Rioja Torres, Juan Besalduch, J. Marín, M.V. Mateos, J M Fernández-Rañada, Jorge Sierra, E Conde,

CNS Lymphoma Diagnosis and Treatment

Abstract Purpose To analyse outcome and prognostic factors for overall survival (OS) and time to treatment failure (TTF) in 357 patients with Hodgkin's lymphoma (HL) undergoing an autologous stem cell transplantation (ASCT) after a first relapse and reported to the The Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO) Cooperative Group. Methods Two hundred and twenty males and 137 females with a median age of 29 years were autografted in second remission ( n =181), first sensitive relapse ( n =148) and first resistant relapse ( n =28). Results Five-year actuarial TTF and OS were of 49%±3% and 57%±3%. Advanced stage at diagnosis, complementary radiotherapy before ASCT, a short first complete response (CR) and detectable disease at ASCT adversely influenced TTF. Year of transplant ≤1995, bulky disease at diagnosis, a short first CR, detectable disease at ASCT and ≥1 extranodal areas involved at ASCT were adverse factors for OS. Conclusions ASCT constitutes a therapeutic option for HL patients after a first relapse. Promising results are observed in patients with low tumour burden at diagnosis, autografted after a long CR and without detectable disease at ASCT. Innovative approaches should be pursued for patients with risk factors at relapse.